• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

    7/11/24 6:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email
    • Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economics
    • Announced Vafseo WAC pricing of $1,278 for a 30-day supply
    • Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025

    Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024

    CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced key updates pertaining to the commercial launch of Vafseo® (vadadustat) Tablets. Akebia will host an investor conference call at 8:00 a.m. ET on Thursday, July 11, 2024.

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    "Since Vafseo approval in late March, our team has worked diligently on commercial launch activities to drive prescriber demand with the goal to optimize Vafseo's revenue ramp during the two-year Transitional Drug Add-on Payment Adjustment (TDAPA) period expected to begin in January 2025 and beyond," said John P. Butler, Chief Executive Officer of Akebia. "This is a multi-faceted endeavor, and today I am excited to share progress made on multiple fronts. First, we have established a wholesale acquisition cost (WAC) that reflects the value of Vafseo in both the dialysis and, if approved, non-dialysis populations. Additionally, contracting effectively with dialysis organizations is critical to a successful launch. To help facilitate the contracting process, as well as simplify the operational management of the product, we have agreed with CSL Vifor to terminate the existing license, resulting in Akebia regaining rights to sell Vafseo to Fresenius Kidney Care dialysis centers and specific other third-party dialysis organizations in the U.S. In addition, we have made significant progress in contract discussions with dialysis organizations for both Auryxia and Vafseo. Having now executed this agreement with CSL Vifor, we can accelerate contracting discussions and expect to have contracts in place with dialysis providers treating the vast majority of eligible Vafseo patients before January 2025. I want to thank our colleagues at CSL Vifor for their collaboration over the past years, and I look forward to continuing to work with them under this new relationship."

    Vafseo Commercial Launch Updates:

    CSL Vifor Agreement: Akebia and CSL Vifor have entered into a termination agreement of the license agreement providing for the payment of royalties by Akebia to CSL Vifor on Vafseo U.S. net product sales. As a result, Akebia regained full rights to sell Vafseo in the U.S. and is able to contract directly with all dialysis organizations effective immediately. Akebia believes its existing and well-established renal sales and medical affairs teams are equipped to drive prescriber demand and enable dialysis organization contracting. Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million. 

    TDAPA Submission: In June, Akebia submitted its TDAPA application. Akebia expects to have Healthcare Common Procedure Coding System (HCPCS) codes assigned in October 2024 and full TDAPA designation by January 1, 2025.

    Vafseo Pricing: Vafseo WAC has been set at $1,278 for a 30-day supply at the minimum starting dose, or approximately $15,500 per year. The entire dialysis business will be a contracted business, offering an off-invoice discount as well as volume tier discounts off this WAC price. The potential label expansion into non-dialysis patients was an important factor in determining the WAC pricing for Vafseo.

    Conference Call Information 

    Akebia will host a conference call on Thursday, July 11, 2024 at 8:00 a.m. Eastern Time to discuss Vafseo commercial updates. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

    A live webcast of the conference call will be available via the "Investors" section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at https://ir.akebia.com approximately two hours after the event.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Forward-Looking Statements

    Statements in this press release regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia's updates pertaining to the commercial launch of Vafseo (vadadustat) Tablets, including that commercial launch activities will drive prescriber demand or optimize Vafseo's revenue ramp during the two-year TDAPA period beginning in January 2025 and beyond, and that the WAC price reflects the value of Vafseo in both the dialysis and, if approved, non-dialysis populations; Akebia's significant progress in contract discussions with dialysis organizations for both Auryxia and Vafseo, including Akebia's expectations for timing to have contracts in place with dialysis providers treating the vast majority of eligible [Vafseo] patients; the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution, improve economics and facilitate the contracting process, including beliefs that Akebia's existing and well-established renal sales and medical affairs teams are equipped to drive prescriber demand and enable dialysis organization contracting; Akebia's expectations for timing to have HCPCS codes and full TDAPA designation; and Akebia's potential label expansion of Vafseo into non-dialysis patients. The terms "intend," "believe," "plan," "goal," "potential," "anticipate, "estimate," "expect," "future," "will," "continue," derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the implementation of the provisions of the termination agreement with CSL Vifor, including the ability of Akebia to successfully contract with dialysis organizations; whether Vafseo will be commercially available when expected; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to, Auryxia® and Vafseo, including estimates regarding the potential market opportunity; the competitive landscape for Auryxia and Vafseo, including potential generic entrants; the ability of Akebia to attract and retain qualified personnel; Akebia's ability to implement cost avoidance measures and reduce operating expenses; decisions made by health authorities, such as the FDA, with respect to regulatory filings; the potential therapeutic benefits, safety profile, and effectiveness of Vafseo; the results of preclinical and clinical research; the direct or indirect impact of the COVID-19 pandemic on the markets and communities in which Akebia and its partners, collaborators, vendors and customers operate; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; and early termination of any of Akebia's collaborations. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

    Akebia Therapeutics®, Auryxia® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc. and its affiliates.

    Akebia Therapeutics Contact

    Mercedes Carrasco

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-provides-update-on-continued-momentum-of-commercial-launch-of-vafseo-vadadustat-tablets-302194243.html

    SOURCE Akebia Therapeutics, Inc.

    Get the next $AKBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    3/31/2022$6.00 → $2.00Buy → Neutral
    Mizuho
    More analyst ratings

    $AKBA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Akebia Therapeutics Inc.

      10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:29:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:04:15 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

      SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

      4/30/25 10:57:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

      Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

      3/28/24 10:46:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Butler John P. sold $84,928 worth of shares (46,409 units at $1.83), decreasing direct ownership by 2% to 2,557,921 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:05:06 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Medical Officer Burke Steven Keith sold $13,074 worth of shares (7,144 units at $1.83), decreasing direct ownership by 0.88% to 809,090 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:04:33 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Butler John P. was granted 701,000 shares and sold $302,925 worth of shares (144,250 units at $2.10), increasing direct ownership by 27% to 2,604,330 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:54:18 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --  Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fir

      5/8/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.41 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of t

      5/1/25 4:15:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Financials

    Live finance-specific insights

    See more
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

      Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

      3/13/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

      3/6/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AKBA
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/13/24 4:58:48 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/24 4:00:47 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/10/23 1:08:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

      Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

      4/28/25 8:36:09 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Akebia Therapeutics with a new price target

      Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

      4/1/25 9:03:14 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Akebia Therapeutics with a new price target

      BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00

      11/29/23 7:10:25 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

      CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

      1/9/24 8:30:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

      CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

      11/1/21 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care